Pregnancy outcome after magnetic resonance–guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids
Presented in part at the 64th Annual Meeting of the American Society for Reproductive Medicine, which was held in San Francisco on November 8–12, 2008.
Received 27 October 2007; received in revised form 28 September 2008; accepted 3 October 2008. published online 14 November 2008.
Objective
To report all pregnancies to date after magnetic resonance–guided focused ultrasound surgery (MRgFUS) for the conservative treatment of clinically significant uterine fibroids.
Design
Prospective registry of all known pregnancies occurring after MRgFUS maintained by the device manufacturer and reported to the Food and Drug Administration.
Setting
World experience of pregnancies after treatment with reports from 13 sites in seven countries.
Patient(s)
Fifty-one reproductive-age women with uterine leiomyomas.
Intervention(s)
Women underwent MRgFUS treatment for symptomatic uterine leiomyomas before this report.
Main Outcome Measure(s)
Pregnancy outcomes and complications.
Result(s)
Fifty-four pregnancies in 51 women have occurred after MRgFUS treatment of uterine leiomyomas. The mean time to conception was 8 months after treatment. Live births occurred in 41% of pregnancies, with a 28% spontaneous abortion rate, an 11% rate of elective pregnancy termination, and 11 (20%) ongoing pregnancies beyond 20 gestational weeks. The mean birth weight was 3.3 kg, and the vaginal delivery rate was 64%.
Conclusion(s)
Preliminary pregnancy experience after MRgFUS is encouraging, with a high rate of delivered and ongoing pregnancies.
aDepartment of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel
bDepartment of Obstetrics and Gynecology, Charite Hospital, Berlin, Germany
cDepartment of Gynecology, Shinsuma General Hospital, Kobe, Japan
dDepartment of Obstetrics and Gynecology, Itabashi Chuo Hospital, Tokyo, Japan
eDepartment of Obstetrics and Gynecology, Mayo Clinic and Mayo College of Medicine, Rochester, Minnesota
fDepartment of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Reprint requests: Elizabeth A. Stewart, M.D., Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905 (FAX: 507-284-1774).
J.R. serves as a clinical trial investigator for Insightec. M.D. has nothing to disclose. H.F. has nothing to disclose. Y.M. has nothing to disclose. B.S.G. has nothing to disclose. E.A.S. serves as a clinical trial investigator for Insightec.
Funding for this study was provided by InSightec (Haifa, Israel).
ABSTRACT